Does TORIPALIMAB Cause Interstitial lung disease? 17 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 17 reports of Interstitial lung disease have been filed in association with TORIPALIMAB (LOQTORZI). This represents 1.3% of all adverse event reports for TORIPALIMAB.
17
Reports of Interstitial lung disease with TORIPALIMAB
1.3%
of all TORIPALIMAB reports
1
Deaths
11
Hospitalizations
How Dangerous Is Interstitial lung disease From TORIPALIMAB?
Of the 17 reports, 1 (5.9%) resulted in death, 11 (64.7%) required hospitalization, and 1 (5.9%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TORIPALIMAB. However, 17 reports have been filed with the FAERS database.
What Other Side Effects Does TORIPALIMAB Cause?
Myelosuppression (590)
Off label use (276)
White blood cell count decreased (144)
Anaemia (67)
Hypothyroidism (67)
Neutrophil count decreased (67)
Nausea (60)
Rash (59)
Vomiting (58)
Platelet count decreased (53)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which TORIPALIMAB Alternatives Have Lower Interstitial lung disease Risk?
TORIPALIMAB vs TORSEMIDE
TORIPALIMAB vs TOVIAZ
TORIPALIMAB vs TOVORAFENIB
TORIPALIMAB vs TOZINAMERAN
TORIPALIMAB vs TRABECTEDIN